Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity

The results of randomized clinical trials employing immune checkpoint inhibitors for pre-treated advanced non-small-cell lung cancer (NSCLC) have recently revolutionised the standard available option for this disease setting. Nevertheless, the validation of reliable predictive biomarkers, able to de...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Transl Lung Cancer Res
Hlavní autoři: Pilotto, Sara, Molina-Vila, Miguel Angel, Karachaliou, Niki, Carbognin, Luisa, Viteri, Santiago, González-Cao, Maria, Bria, Emilio, Tortora, Giampaolo, Rosell, Rafael
Médium: Artigo
Jazyk:Inglês
Vydáno: AME Publishing Company 2015
Témata:
Review Article on Lung Cancer Immunotherapy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4700230/
https://ncbi.nlm.nih.gov/pubmed/26798581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.10.11
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky